© Michael Ciaglo/Getty Images News via Getty Images
There have been a lot of changes in the markets recently, inflation has come down but growth has been uneven and volatility is still lurking around every corner of earnings. Smart investors know that one truth remains constant: reliable earnings beat the hype every time.
That’s why you should consider owning a healthcare company that has grown its dividend despite recessions, pandemics and patent difficulties — without missing a beat. johnson and johnson (NYSE:JNJ | jnj price prediction) is a dividend king that just doesn’t pay; This provides stability that allows shareholders to sleep peacefully during broader market fluctuations.
Dividend legacy built on 63 years of growth
Johnson & Johnson has increased its dividend 63 consecutive yearsAnd it is set to deliver its 64th annual increase when it reports first-quarter 2026 earnings before markets open on April 14. This track record is not luck – it is the result of disciplined capital allocation across its diverse portfolio of drugs, medical devices and consumer health products.
Last year, Johnson & Johnson raised its quarterly payout from $1.24 to $1.30 per share, an increase of about 5%. The stock now yields 2.14% annualized at $5.20 per share. Over the past decade, it has delivered 5% compound annual growth. The payout ratio also sits at a comfortable 46.7%, leaving plenty of room for reinvestment or further appreciation. In short, this is no high-yield trap – it’s a machine built for consistent growth for decades to come.
Financial results that speak louder than headlines
Let’s take a look at the numbers that support this. Johnson & Johnson’s full-year 2025 results project sales of $94.2 billion, up 6% from 2024. Even taking into account the loss of exclusivity on Stelara, operating growth reached 5.3%. Sales of innovative medicines alone topped $60 billion for the first time, with 13 brands growing double digits.
Adjusted earnings reached $10.79 per share, an increase of 8.1% from last year. Free cash flow came to approximately $19.7 billion, which financed $12.4 billion in dividends paid to shareholders and more than $32 billion in R&D plus strategic acquisitions. The balance sheet remains strong, with approximately $28 billion of net debt against approximately $20 billion of cash and marketable securities.
No matter how you look at it, these figures show a company that generates cash that it’s able to share — without exaggerating.
Stability wins compared to peers
Investors often chase higher yields elsewhere in the healthcare sector, but Johnson & Johnson is favorably positioned when you compare the whole picture. Here’s how it stacks up against its two major rivals, based on the latest available data:
| metric | johnson and johnson | Pfizer (NYSE:PFE) | merck (NYSE: MRK) |
| dividend yield | 2.14% | 6.20% | 2.88% |
| payout ratio | 46.7% | 118.6% | 45.8% |
| Continuous dividend increases | 63 years | 16 years | 15 years |
| 5-Year Average Annual Dividend Growth | 5.25% | 2.5% | 7% |
Pfizer’s skyrocketing yield comes with real risk – its payout ratio above 100% indicates pressure coming in. Merck offers solid growth but Johnson & Johnson falls short Comprehensiveness and decades-long reliability. Johnson & Johnson also trades at a normalized P/E of around 22.45, which is a reasonable premium for its low volatility and proven cash generation.
That said, no stock is risk-free. Ongoing litigation and patent expirations remain items to monitor, but Johnson & Johnson’s diverse pipeline — 28 platforms now generating more than $1 billion annually — enables it to weather those challenges.
key takeaway
Don’t bet against this dividend king. With earnings due April 14 and a 64th dividend increase on the horizon, Johnson & Johnson offers retail investors a rare combination: a 2.14% yield today, a low payout ratio for future growth, and a business model built to quietly grow wealth. Add this to the income and peace of mind – your portfolio will thank you.